TABLE 4.

Comparison of Diagnostic Efficacy Between ⁶⁸Ga-FAPI and ¹⁸F-FDG PET (Per-Patient and Per-Region Analysis) for Tumors in Which ⁶⁸Ga-FAPI Underperformed in Comparison to ¹⁸F-FDG PET

Tumor entity	n	Stratification	PET-positive/total	Sensitivity	Specificity	PPV	NPV	Accuracy
⁶⁸Ga-FAPI PET
Bladder	12	Per-patient	8/12	72.7 (39–94)	100 (2.5–100)	100	25 (11.3–46.7)	75 (42.8–94.5)
		Per-region	12/37	78.6 (49.2–95.3)	95.7 (78.1–99.9)	91.7 (61.34–98.7)	88 (72.8–95.3)	89.2 (74.6–97)
Kidney	10	Per-patient	8/10	87.5 (47.4–99.7)	50 (1.26–98.7)	87.5 (63.1–96.6)	50 (9.13–90.9)	80 (44.4–97.5)
		Per-region	15/31	92.9 (66.1–99.8)	88.2 (63.6–98.5)	86.7 (63.7–96)	93.8 (69.2–99)	90.3 (74.3–98)
Lymphoma	9	Per-patient	7/9	87.5 (47.4–99.7)	100 (2.5–100)	100	50 (13.8–86.2)	88.9 (51.8–99.7)
		Per-region	11/30	78.6 (49.2–95.3)	100 (79.4–100)	100	84.2 (66.2–93.6)	90 (73.5–97.9)
Myeloma	10	Per-patient	6/10	75 (34.9–96.8)	100 (15.8–100)	100	50 (23.1–76.9)	80 (44.4–97.5)
		Per-region	6/10	75 (34.9–96.8)	100 (15.8–100)	100	50 (23.1–76.9)	80 (44.4–97.5)
¹⁸F-FDG PET
Bladder	12	Per-patient	11/12	100 (71.5–100)	100 (2.5–100)	100	100	100 (73.5–100)
		Per-region	13/36	92.3 (64–99.8)	95.7 (78.1–99.9)	92.31 (63.7–98.8)	95.7 (77–99.3)	94.4 (81.3–99.3)
Kidney	10	Per-patient	7/10	87.5 (47.4–99.7)	100 (15.8–100)	100	66.7 (24.2–92.6)	90 (55.5–99.8)
		Per-region	14/31	92.9 (66.1–99.8)	94.1 (71.3–99.9)	92.9 (65.9–98.9)	94.12 (70.7–99.1)	93.55 (78.6–99.2)
Lymphoma	9	Per-patient	8/9	100 (63.1–100)	100 (2.5–100)	100	100	100 (66.4–100)
		Per-region	15/30	100 (76.8–100)	93.8 (69.8–99.8)	93.33 (67.7–98.9)	100	96.7 (82.8–99.9)
Myeloma	10	Per-patient	7/10	87.5 (47.4–99.7)	100 (15.8–100)	100	66.7 (24.2–92.6)	90 (55.5–99.8)
		Per-region	7/10	87.5 (47.4–99.7)	100 (15.8–100)	100	66.7 (24.2–92.6)	90 (55.5–99.8)

Data in parentheses are 95% CI.